Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction

Exclusion Criteria

• •treated by a combination regimen containing all the study drugs;
• •allergy to any of the study drugs;
• •HER-2 amplification or overexpression, mismatch repair protein expression deletion (dMMR), or genetic testing suggestive of high microsatellite instability (MSI-H);
• •strangulated intestinal obstruction;
• •active gastrointestinal bleeding;
• •uncontrolled active infection;
• •unstable heart diseases with severe ECG abnormalities or affect clinical treatment (such as cardiac insufficiency, myocardial infarction, angina);
• •severe lung diseases (such as interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc);
• •mental disorders that affect clinical treatment or central nervous system diseases;
• •concomitant cerebral parenchymal or meningeal metastasis;
• •HIV infection or untreated active hepatitis;
• •bowel surgery or stenting required due to obstruction;
• •pregnant or lactating women;
• •other conditions that are not suitable for participation in the study.